ELAVAY / Sample Intelligence

What the data actually says

A glimpse of real ELAVAY findings, the kind of evidence that turns a resourcing conversation into a strategic decision. These are samples; your reports are specific to your communities.

0%
of advocates rate non-medical switching as a high-impact barrier to care.
0%
see limited patient education about copay-assistance programs.
0%
of materials are written above a 5th-6th-grade reading level.

Top barriers to access

Share of advocates rating each as high-impact · sample
Non-medical switching49.5%
Prior authorization44.1%
Step therapy38.2%
Copay accumulators33.4%
Risk, barrier to access

BioAdvocate team scope

Avg. advocacy headcount by number of disease states · sample
1-3 disease states5
4-7 disease states9
8+ disease states50
Informational, team scale
In their words

The verbatims behind the numbers

Qualitative depth is where ELAVAY earns its trust. A few representative advocate voices.

"Until you know the community's perception, you really don't know if you're effective."

Advocacy Leader · Sample ELAVAY interview

"The granular comments give us better insight into the challenges patients actually face."

Advocacy Leader · Sample ELAVAY interview

Want the full sample report?

Get a representative 2025 ELAVAY sample, methodology, benchmark tables, and need-gap analysis, sent to your inbox.

Download the sample

See your numbers

This is what a sample looks like. Your ELAVAY reports speak directly to your disease areas and communities.